Postoperative Pain Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Postoperative Pain pipeline constitutes 40+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Postoperative Pain Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Postoperative Pain Market.

The Postoperative Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Postoperative Pain Pipeline Report: https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Postoperative Pain treatment therapies with a considerable amount of success over the years.
• Postoperative Pain companies working in the treatment market are InSitu Biologics, Bexson Biomedical, Allay Therapeutics, SiteOne Therapeutics, LipoCure, Flexion Therapeutics, Nevakar, Inc., Jiangsu HengRui Medicine Co., Ltd., Concentric Analgesics, Oculis Pharma, Haisco Pharmaceutical Group, Vivozon Pharmaceutical Inc, and others, are developing therapies for the Postoperative Pain treatment
• Emerging Postoperative Pain therapies in the different phases of clinical trials are- INSB-200, BB-106, ATX-201, ST-2427, LC-400, FX 301, NVK-009, HR021618, CA-008, OCS-01, HSK21542, VVZ-149, and others are expected to have a significant impact on the Postoperative Pain market in the coming years.
• In May 2025, HSK21542, a peripherally restricted kappa opioid receptor agonist, was studied for its effectiveness and safety in managing postoperative pain following abdominal surgery. The evaluation was conducted through two Phase 3, multicenter, randomized, double-blind, controlled trials in China: HSK21542-301 (ClinicalTrials.gov ID: NCT04738357) and HSK21542-303 (ClinicalTrials.gov ID: NCT05390905). The HSK21542-301 trial compared HSK21542 at a dose of 1.0 μg/kg with a placebo in a two-arm study, while HSK21542-303 was a three-arm study comparing HSK21542 1.0 μg/kg, and placebo. All treatments were given via intravenous administration.
• In February 2025, Allay Therapeutics has administered the first dose in the randomized Phase IIb registration trial of its investigational analgesic, ATX101, intended to deliver prolonged pain relief after total knee replacement surgery. The treatment seeks to reduce opioid use and improve patient recovery. This three-arm, controlled study involves 200 participants undergoing total knee arthroplasty (TKA) and is being carried out at multiple sites across the United States.

Postoperative Pain Overview
Postoperative pain refers to the discomfort or pain experienced by patients after undergoing a surgical procedure. It results from tissue damage, inflammation, and nerve irritation caused during surgery. Managing postoperative pain is crucial to promote healing, improve patient comfort, and prevent complications such as delayed recovery or chronic pain. Treatment typically includes medications like opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and sometimes nerve blocks or regional anesthesia. Effective pain management also supports early mobilization and reduces the risk of post-surgical complications.

Get a Free Sample PDF Report to know more about Postoperative Pain Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Postoperative Pain Drugs Under Different Phases of Clinical Development Include:
• INSB-200: InSitu Biologics
• BB-106: Bexson Biomedical
• ATX-201: Allay Therapeutics
• ST-2427: SiteOne Therapeutics
• LC-400: LipoCure
• FX 301: Flexion Therapeutics
• NVK-009: Nevakar, Inc.
• HR021618: Jiangsu HengRui Medicine Co., Ltd.
• CA-008: Concentric Analgesics
• OCS-01: Oculis Pharma
• HSK21542: Haisco Pharmaceutical Group
• VVZ-149: Vivozon Pharmaceutical Inc

Postoperative Pain Route of Administration
Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Postoperative Pain Molecule Type
Postoperative Pain Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Postoperative Pain Pipeline Therapeutics Assessment
• Postoperative Pain Assessment by Product Type
• Postoperative Pain By Stage and Product Type
• Postoperative Pain Assessment by Route of Administration
• Postoperative Pain By Stage and Route of Administration
• Postoperative Pain Assessment by Molecule Type
• Postoperative Pain by Stage and Molecule Type

DelveInsight's Postoperative Pain Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Postoperative Pain product details are provided in the report. Download the Postoperative Pain pipeline report to learn more about the emerging Postoperative Pain therapies
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Postoperative Pain Therapeutics Market include:
Key companies developing therapies for Postoperative Pain are - Novartis AG, Allergan, Mylan N.V, Pfizer, Purdue Pharma, Teva Pharmaceutical, Janssen Pharmaceuticals, Endo International, and others.

Postoperative Pain Pipeline Analysis:
The Postoperative Pain pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Postoperative Pain with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain Treatment.
• Postoperative Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Postoperative Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postoperative Pain market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Postoperative Pain drugs and therapies
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Postoperative Pain Pipeline Market Drivers
• Rise in the number of surgical procedures worldwide, government's initiative to promote better postoperative pain treatment are some of the important factors that are fueling the Postoperative Pain Market.

Postoperative Pain Pipeline Market Barriers
• However, adverse effects associated with the medications, research Gaps in Practice Guidelines for Acute Postoperative Pain Management and other factors are creating obstacles in the Postoperative Pain Market growth.

Scope of Postoperative Pain Pipeline Drug Insight
• Coverage: Global
• Key Postoperative Pain Companies: InSitu Biologics, Bexson Biomedical, Allay Therapeutics, SiteOne Therapeutics, LipoCure, Flexion Therapeutics, Nevakar, Inc., Jiangsu HengRui Medicine Co., Ltd., Concentric Analgesics, Oculis Pharma, Haisco Pharmaceutical Group, Vivozon Pharmaceutical Inc, and others
• Key Postoperative Pain Therapies: INSB-200, BB-106, ATX-201, ST-2427, LC-400, FX 301, NVK-009, HR021618, CA-008, OCS-01, HSK21542, VVZ-149, and others
• Postoperative Pain Therapeutic Assessment: Postoperative Pain current marketed and Postoperative Pain emerging therapies
• Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsigh
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.